Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 3

The Evolving First-line Treatment Approach for DLBCL

, , , , ,

An exploration of how first-line treatment practices for DLBCL have evolved with new options, emphasizing the role of relapsed/refractory disease risk in guiding treatment selection.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Emerging Updates in Front-line Treatment Approach of DLBCL
    EP. 2: Insights from POLARIX: How do Novel Perspectives Influence Treatment Outcomes in DLBCL?
    Now Viewing
    EP. 3: The Evolving First-line Treatment Approach for DLBCL
    EP. 4: Future Considerations for Front-line Treatment of DLBCL
    EP. 5: Role of Testing in Treatment Decisions - ClonoSeq, PhaseSeq, MRD+Disease
    EP. 6: Second-line Treatment Landscape in Relapsed/Refractory DLBCL
    EP. 7: The Emerging Role of Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL
    EP. 8: Safety Considerations for Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL
    EP. 9: Real World Perspectives: Outcomes for CAR T-cell Therapy in Relapsed/Refractory DLBCL
    EP. 10: Real World Perspectives: Considerations and Challenges for CAR T-cell Therapy in Relapsed/Refractory DLBCL
    EP. 11: Additional Perspectives Beyond CAR T-cell Regimens in Relapsed/Refractory DLBCL.: Bispecifics
    EP. 12: Academic Insights for the Treatment of Later Relapsed/Refractory DLBCL
    EP. 13: Bispecific Antibodies in the Relapsed/Refractory DLBCL Treatment Landscape
    EP. 14: Future Perspectives for the Treatment of Relapsed/Refractory DLBCL

    Video content above is prompted by the following:

    • In recent years, how has your practice changed with new 1L treatment options available?
    • What role does the potential for relapsed/refractory (RR) disease play in 1L treatment selections?
    x